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Abstract 
 
Tumor suppressor p53 is a multifunctional transcription factor that regulates diverse cell 
fates, including apoptosis and autophagy in tumor biology. p53 overexpression enhances 
the antitumor activity of oncolytic adenoviruses; however, the molecular mechanism of 
this occurrence remains unclear. We previously developed a tumor-specific 
replication-competent oncolytic adenovirus, OBP-301, that kills human osteosarcoma 
cells, but some human osteosarcoma cells were OBP-301-resistant. In this study, we 
investigated the antitumor activity of a p53-expressing oncolytic adenovirus, OBP-702, 
and the molecular mechanism of the p53-mediated cell death pathway in 
OBP-301-resistant human osteosarcoma cells. The cytopathic activity of OBP-702 was 
examined in OBP-301-sensitive (U2OS and HOS) and OBP-301-resistant (SaOS-2 and 
MNNG/HOS) human osteosarcoma cells. The molecular mechanism in the 
OBP-702-mediated induction of two cell death pathways, apoptosis and autophagy, was 
investigated in OBP-301-resistant osteosarcoma cells. The antitumor effect of OBP-702 
was further assessed using an orthotopic OBP-301-resistant MNNG/HOS osteosarcoma 
xenograft tumor model. OBP-702 suppressed the viability of OBP-301-sensitive and 
OBP-301-resistant osteosarcoma cells more efficiently than OBP-301 or a 
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replication-deficient p53-expressing adenovirus (Ad-p53). OBP-702 induced more 
profound apoptosis and autophagy when compared with OBP-301 or Ad-p53. 
E1A-mediated miR-93/106b upregulation induced p21 suppression, leading to 
p53-mediated apoptosis and autophagy in OBP-702-infected cells. p53 overexpression 
enhanced adenovirus-mediated autophagy through activation of damage-regulated 
autophagy modulator (DRAM). Moreover, OBP-702 suppressed tumor growth in an 
orthotopic OBP-301-resistant MNNG/HOS xenograft tumor model. These results 
suggest that OBP-702-mediated p53 transactivation is a promising antitumor strategy to 
induce dual apoptotic and autophagic cell death pathways via regulation of miRNA and 
DRAM in human osteosarcoma cells. 
 
Key words: oncolytic adenovirus; telomerase; p53; apoptosis; autophagy 
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Introduction 
 
Osteosarcoma is one of the most common malignant tumors in young children 
(1, 2). Current treatment strategies, which consist of multi-agent chemotherapy and 
aggressive surgery, have significantly improved the cure rate and prognosis of patients 
with osteosarcoma. In fact, over the past 30 years, the 5-year survival rate has increased 
from 10% to 70% (3-5). Even in osteosarcoma patients with metastases at diagnosis, the 
5-year survival rate has reached 20% to 30% in response to chemotherapy and surgical 
removal of primary and metastatic tumors (6). However, treatment outcomes for 
patients with osteosarcomas have further improved over the last few years. Therefore, 
the development of novel therapeutic strategies is required to improve the clinical 
outcomes in patients with osteosarcomas. 
Tumor-specific replication-competent oncolytic viruses are being developed as 
novel anticancer therapy, in which the promoters of cancer-related genes are used to 
regulate virus replication in a tumor-dependent manner. More than 85% of all human 
cancers express high telomerase activity to maintain the length of the telomeres during 
cell division, while normal somatic cells seldom show this enhance telomerase activity 
(7, 8). Telomerase activity has also been detected in 44% to 81% of bone and soft tissue 
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sarcomas (9, 10). Telomerase activation is closely correlated with the expression of the 
human telomerase reverse transcriptase (hTERT) gene (11). Based on these data, we 
previously developed a telomerase-specific replication-competent oncolytic adenovirus 
OBP-301 (Telomelysin), in which the hTERT gene promoter drives the expression of 
the E1A and E1B genes (12). A phase I clinical trial of OBP-301, which was conducted 
in the United States on patients with advanced solid tumors, indicated that OBP-301 
was well tolerated by patients (13). Recently, we reported that OBP-301 efficiently 
killed human bone and soft tissue sarcoma cells (14, 15). However, some osteosarcoma 
cell lines were not sensitive to the antitumor effect of OBP-301. Therefore, to efficiently 
eliminate tumor cells with OBP-301, its antitumor effects need to be enhanced. 
Cancer gene therapy is defined as the treatment of malignant tumors via the 
introduction of a therapeutic tumor suppressor gene or the abrogation of an oncogene. 
The tumor-suppressor p53 gene has an attractive tumor suppressor profile as a potent 
therapeutic transgene for induction of cell cycle arrest, senescence, apoptosis and 
autophagy (16). Dual cell death pathways, such as apoptosis and autophagy, induced by 
p53 transactivation are mainly involved in the suppression of tumor initiation and 
progression. However, among the p53-downstream target genes, p21, which is most 
rapidly and strongly induced during the DNA damage response, mainly induces cell 
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cycle arrest through suppression of apoptotic and autophagic cell death pathways (17, 
18). Thus, p21 suppression may be a more effective strategy for the induction of 
apoptotic and autophagic cell death pathways in tumor cells, particularly when the 
tumor-suppressor p53 gene is overexpressed in tumor cells in response to cancer gene 
therapy. 
A p53-expressing replication-deficient adenovirus (Ad-p53, Advexin) has 
previously been reported to induce an antitumor effect in the in vitro and in vivo settings 
(19, 20) as well as in some clinical studies (21-24). We recently reported that 
combination therapy with OBP-301 and Ad-p53 resulted in a more profound antitumor 
effect when compared to monotherapy with either OBP-301 or Ad-p53 (25). Moreover, 
we generated armed OBP-301 expressing the wild-type p53 tumor suppressor gene 
(OBP-702) and showed that OBP-702 suppressed the viability of various types of 
epithelial malignant cells more efficiently than did OBP-301 (26). OBP-702 induced a 
more profound apoptotic cell death effect when compared to Ad-p53, likely via 
adenoviral E1A-mediated suppression of anti-apoptotic p21 in human epithelial 
malignant cells. However, it remained unclear whether OBP-702 efficiently induces an 
antitumor effect in human non-epithelial malignant cells, including osteosarcomas. 
In the present study, we investigated the in vitro cytopathic efficacy of the 
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p53-expressing telomerase-specific replication-competent oncolytic adenovirus, 
OBP-702, in human osteosarcoma cells, and we compared the induction level of 
apoptotic and autophagic cell deaths in OBP-301-resistant human osteosarcoma cells 
infected with OBP-301, OBP-702 and Ad-p53. The molecular mechanism by which 
OBP-702 mediates induction of apoptosis and autophagy was also investigated. Finally, 
the in vivo antitumor effect of OBP-702 was evaluated using an orthotopic 
OBP-301-resistant human osteosarcoma xenograft tumor model. 
 
Materials and Methods 
 
Cell lines 
The human osteosarcoma cell lines, HOS and SaOS-2, were kindly provided 
by Dr. Satoru Kyo (Kanazawa University, Ishikawa, Japan). These cells were 
propagated as monolayer cultures in Dulbecco’s modified Eagle’s medium. The human 
osteosarcoma cell line, U2OS, was obtained from the American Type Culture Collection 
(Manassas, VA, USA) and was grown in McCoy’s 5a medium. The human 
osteosarcoma cell line, MNNG/HOS, was purchased from DS Pharma Biomedical 
(Osaka, Japan) and was maintained in Eagle’s minimum essential medium containing 
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1% nonessential amino acids. All media were supplemented with 10% fetal bovine 
serum, 100 U/ml penicillin and 100 mg/ml streptomycin. The normal human lung 
fibroblast cell line, NHLF, was obtained from TaKaRa Biomedicals (Kyoto, Japan). 
NHLF cells were propagated as monolayer culture in the medium recommended by the 
manufacturer. Although cell lines were not authenticated by the authors, cells were 
immediately expanded after receipt and stored in liquid N2. Cells were not cultured for 
more than 5 months following resuscitation. The cells were maintained at 37C in a 
humidified atmosphere with 5% CO2. 
 
Recombinant adenoviruses 
The recombinant telomerase-specific replication-competent adenovirus 
OBP-301 (Telomelysin), in which the promoter element of the hTERT gene drives the 
expression of E1A and E1B genes, was previously constructed and characterized (12, 
27). For OBP-301-mediated induction of exogenous p53 gene expression, we recently 
generated OBP-702, in which a human wild-type p53 gene expression cassette was 
inserted into the E3 region (Supplementary Fig. S1) (26). Ad-p53 is a 
replication-defective adenovirus serotype 5 vector with a p53 gene expression cassette 
at the E1 region (19, 20). Recombinant viruses were purified by ultracentrifugation 
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using cesium chloride step gradients, their titers were determined by a plaque-forming 
assay using 293 cells, and they were stored at -80C. 
 
Cell viability assay 
Cells were seeded on 96-well plates at a density of 1 × 10
3
 cells/well 24 h 
before viral infection. All cell lines were infected with OBP-702 at multiplicity of 
infections (MOI) of 0, 0.1, 1, 10, 50 or 100 plaque forming units (PFU)/cell. Cell 
viability was determined on days 1, 2, 3 and 5 after virus infection using Cell 
Proliferation Kit II (Roche Molecular Biochemicals, Indianapolis, IN, USA). The 50% 
inhibiting dose (ID50) value of OBP-702 for each cell line was calculated using cell 
viability data obtained on day 5 after virus infection. 
 
Time-lapse confocal laser microscopy 
Green fluorescent protein (GFP)-expressing MNNG/HOS (MNNG/HOS-GFP) 
cells were established by stable transfection with GFP expression plasmid using 
Lipofectamine LTX (Invitrogen, Carlsbad, CA, USA). MNNG/HOS-GFP and NHLF 
cells were seeded in 35-mm glass-based dishes at a density of 1 × 10
5
 cells/dish 24 h 
before infection and were infected with OBP-702 at an MOI of 10 PFU/cell for 72 h. 
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Phase-contrast and fluorescence time-lapse recordings were obtained to concomitantly 
analyze cell morphology and GFP expression using an inverted FV10i confocal laser 
scanning microscopy (OLYMPUS; Tokyo, Japan). 
 
Western blot analysis 
SaOS-2 and MNNG/HOS cells, seeded in a 100-mm dish at a density of 1 × 
10
5
 cells/dish, were infected with OBP-301, OBP-702 or Ad-p53 at the indicated MOIs. 
In contrast, SaOS-2 cells were transfected with 10 nM miR-93 (Ambion, Austin, TX, 
USA), miR-106b (Ambion) or control miRNA (Ambion) 24 h before Ad-p53 infection 
and infected with Ad-p53 at an MOI of 100 for 48 h. Whole-cell lysates were prepared 
in a lysis buffer (50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton X-100) 
containing a protease inhibitor cocktail (Complete Mini; Roche, Indianapolis, IN, USA) 
at the indicated time points. Proteins were electrophoresed on 6% to 15% sodium 
dodecyl sulfate polyacrylamide gels and were transferred to polyvinylidene difluoride 
membranes (Hybond-P; GE Health Care, Buckinghamshire, UK). Blots were blocked 
with 5% non-fat dry milk in TBS-T (Tris-buffered saline and 0.1% Tween-20, pH 7.4). 
The primary antibodies used were: rabbit anti-PARP polyclonal antibody (pAb) (Cell 
Signaling Technology, Beverly, MA, USA), mouse anti-p53 monoclonal antibody 
Hasei et al., Page 12 
(mAb) (Calbiochem, Darmstadt, Germany), mouse anti-p21
WAF1
 mAb (Calbiochem), 
rabbit anti-E2F1 pAb (Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse 
anti-Ad5 E1A mAb (BD PharMingen, Franklin Lakes, NJ, USA), rabbit 
anti-microtubule-associated protein 1 light chain 3 (LC3) pAb (Medical & Biological 
Laboratories (MBL), Nagoya, Japan), mouse anti-p62 mAb (MBL), rabbit anti- 
damage-regulated autophagy modulator (DRAM) pAb (Abgent, San Diego, CA, USA), 
and mouse anti-β-actin mAb (Sigma-Aldrich, St. Louis, MO, USA).  
 
Flow cytometric analysis 
To analyze the active caspase-3 expression, cells were incubated for 20 min on 
ice in Cytofix/Cytoperm solution (BD Biosciences, Franklin Lakes, NJ, USA), were 
labeled with phycoerythrin-conjugated rabbit anti-active caspase-3 mAb (BD 
Biosciences) for 30 min, and were then analyzed using FACS array (BD Biosciences).    
To evaluate the sub-G1 population, which is a apoptosis indicator, in SaOS-2 
cells after virus infection, SaOS-2 cells were seeded in a 100-mm dish at a density of 1 
x 10
6
 cells/dish 24 h before viral infection, and were infected with mock, OBP-301, 
Ad-p53 or OBP-702 at an MOI of 10 PFUs/cell for 48 h. Cells were trypsinized and 
resuspended in original supernatant to ensure that both attached and non-attached cells 
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were analyzed. Cells stained with propidium iodide were analyzed using FACS array 
(BD Bioscience, Franklin Lakes, NJ, USA). 
 
Quantitative real-time reverse transcription-PCR analysis 
To evaluate the expressions of miR-93 and miR-106b in tumor cells after 
OBP-702 infection, SaOS-2 and MNNG/HOS cells were seeded on 6-well plates at a 
density of 2 × 10
5
 cells/well 24 h before viral infection and were infected with OBP-702 
at MOIs of 0, 1, 5, 10, 50 or 100 PFU/cell. Three days after virus infection, total RNA 
was extracted from the cells using a miRNeasy Mini kit (Qiagen, Valencia, CA, USA). 
The concentration and quality of RNA were assessed using a Nanodrop 
spectrophotometer. cDNA was synthesized from 10 ng of total RNA using the TaqMan 
MicroRNA Reverse Transcription kit (Applied Biosystems), and quantitative real-time 
RT-PCR was performed using the Applied Biosystems StepOnePlus
TM
 real-time PCR 
System. The expressions of miR-93 and miR-106b were defined from the threshold 
cycle (Ct), and relative expression levels were calculated using the 2
-Ct
 method after 
normalization with reference to the expression of U6 snRNA. 
 
In vivo orthotopic MNNG/HOS xenograft tumor model 
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Animal experimental protocols were approved by the Ethics Review 
Committee for Animal Experimentation of Okayama University School of Medicine. 
MNNG/HOS cells (5 × 10
6
 cells per site) were inoculated into the tibias of female 
athymic nude mice aged 6 to 7 weeks (CLEA Japan, Tokyo, Japan). Palpable tumors 
developed within 21 days and were permitted to grow to approximately 5 to 6 mm in 
diameter. At that stage, a 50-l volume of solution containing OBP-702, OBP-301 or 
Ad-p53 at a dose of 1 × 10
8
 PFU or phosphate buffered saline (PBS) was injected into 
the tumors for three cycles every 2 days. Tumor volume was monitored by computed 
tomography (CT) imaging once a week after virus infection. 
 
Three-dimensional computed tomography imaging 
The tumor volume and formation of osteolytic lesions were evaluated using 
three-dimensional computed tomography (3D-CT) imaging (ALOKA Latheta LCT-200; 
Hitachi Aloka Medical, Tokyo, Japan). The tumor volume was calculated by INTAGE 
Realia
®
 software (Cybernet Systems, Tokyo, Japan). 
 
Histopathologic analysis 
Tumors were fixed in 10% neutralized formalin and embedded in paraffin 
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blocks. Sections were stained with hematoxylin/eosin (H&E) and analyzed by light 
microscopy. 
 
Statistical analysis 
Data are expressed as means ± SD. Student’s t test was used to compare 
differences between groups. Statistical significance was defined as a P value less than 
0.05. 
 
Results 
 
In vitro cytopathic efficacy of OBP-702 against human osteosarcoma cell lines 
To evaluate the in vitro cytopathic activity of OBP-702, we used the two 
OBP-301-sensitive human osteosarcoma cells (HOS and U2OS) and the two 
OBP-301-resistant human osteosarcoma cells (SaOS-2 and MNNG/HOS) that were 
recently described (14). The cell viability of each cell was assessed over 5 days after 
infection using the XTT assay. OBP-702 infection suppressed the viability of 
OBP-301-sensitive and OBP-301-resistant cells in dose- and time-dependent manners 
(Fig. 1A and 1B). When the ID50 values of OBP-702 in all four human osteosarcoma 
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cells were compared with those of OBP-301 calculated in a previous report (14), all cell 
lines were more sensitive to OBP-702 than to OBP-301 (Table 1). The ID50 values of 
OBP-702 were also lower than those of Ad-p53 (Supplementary Fig. S2). However, 
OBP-702 did not exhibit any cytopathic effect in NHLF cells (Fig. 1B). When 
GFP-expressing MNNG/HOS-GFP cells were co-cultured with human normal NHLF 
cells, OBP-702 infection showed a cytopathic effect (confirmed by observation of 
round-shaped morphological changes) in MNNG/HOS-GFP cells, but not in NHLF cells 
(Fig. 1C). These results indicate that OBP-702 was more cytopathic than OBP-301 for 
human osteosarcoma cells, but was not cytopathic for normal human cells. 
 
Increased induction of apoptosis by OBP-702 when compared with OBP-301 or 
Ad-p53 
We next investigated whether OBP-702 induces more profound apoptosis when 
compared with OBP-301 or Ad-p53. OBP-301-resistant SaOS-2 and MNNG/HOS cells 
were infected with OBP-702, OBP-301 or Ad-p53, and apoptosis was assessed by 
Western blot and flow cytometric analyzes. Western blot analysis showed that SaOS-2 
cells exhibited the cleavage of PARP after infection with OBP-702 (more than 5 MOIs) 
or Ad-p53 (more than 50 MOIs), whereas MNNG/HOS cells had the cleavage of PARP 
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after infection with OBP-702 (more than 5 MOIs), but not Ad-p53 (Fig. 2A). In contrast, 
OBP-301 did not induce apoptosis (data not shown). Furthermore, flow cytometric 
analysis demonstrated that OBP-702 infection (10 MOIs) significantly increased the 
percentage of apoptotic cells with active caspase-3 when compared with Ad-p53 or 
OBP-301 at same doses in SaOS-2 and MNNG/HOS cells (Fig. 2B and 2C). Cell cycle 
analysis also showed that OBP-702 (10 MOIs) induced the highest percentages of 
sub-G1 population in SaOS-2 cells when compared with Ad-p53 or OBP-301 at same 
doses (Fig. 2D). These results suggest that OBP-702 induces increased apoptosis when 
compared with Ad-p53 or OBP-301 in human osteosarcoma cells. 
 
p53 induction in human osteosarcoma cells infected with OBP-702 
To investigate the molecular mechanism of OBP-702-induced apoptosis in 
human osteosarcoma cells, we evaluated p53 expression after OBP-702 infection in 
SaOS-2 (p53 null) and MNNG/HOS (p53 mutant) cells in which endogenous p53 
expression level was confirmed by Western blot analysis (Supplementary Fig. S3). 
OBP-702 efficiently induced p53 expression in SaOS-2 and MNNG/HOS cells (Fig. 
3A). The level of p53 expression was higher in OBP-702-treated cells than in 
Ad-p53-treated cells (Fig. 3A). In spite of OBP-702-induced high p53 expression, 
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p53-downstream target p21 protein was induced only in Ad-p53-treated cells. 
To investigate the effect of exogenous p53 overexpression in virus replication, 
we next compared the replication abilities of OBP-702 and OBP-301 in p53-null 
SaOS-2 cells by measuring the relative amounts of E1A copy numbers. The E1A copy 
number of OBP-702 was similar to that of OBP-301 in SaOS-2 cells (Supplementary 
Fig. S4). These results indicate that OBP-702 efficiently induces exogenous p53 
expression without affecting p21 expression and virus replication in human 
osteosarcoma cells. 
 
OBP-702-mediated upregulation of miR-93 and miR-106b suppresses p21 
expression 
Adenoviral E1A protein has been shown to activate E2F1 expression (28), 
which is a multifunctional transcription factor that regulates diverse cell fates through 
induction of many target genes, including small non-coding microRNAs (miRNAs) (29). 
Recently, E2F1-inducible miR-93 and miR-106b have been shown to suppress p21 
expression in human cancer cells (30). Therefore, we sought to investigate whether 
OBP-702 induces expressions of E2F1 and E2F1-regulated miRNAs (miR-93 and 
miR-106b). OBP-702 infection activated E2F1 expression along with E1A accumulation 
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in SaOS-2 and MNNG/HOS cells (Fig. 3B). The expression levels of miR-93 and 
miR-106b were increased in association with E2F1 activation in OBP-702-infected 
SaOS-2 and MNNG/HOS cells (Fig. 3C). In contrast, E1A-deleted Ad-p53 infection did 
not increase expressions of E2F1 and E2F1-regulated miR-93 and miR-106b (data not 
shown). Next, we assessed whether upregulation of miR-93 and miR-106b efficiently 
suppresses p21 expression induced by Ad-p53-mediated p53 overexpression. Ad-p53 
infection at MOIs of 10 and 100 efficiently induced p21 expression at 48 h after 
infection in SaOS-2 cells (Supplementary Fig. S5). When SaOS-2 cells were infected 
with Ad-p53 at an MOI of 100 for 48 h, pre-transfection with miR-93, miR-106b or both 
efficiently suppressed Ad-p53-induced p21 expression (Fig. 3D). Interestingly, both 
miR-93 and miR-106b -transfected SaOS-2 cells showed the 1.5-fold increased 
expression of cleaved PARP (C-PARP) in consistent with remarkable p21 
downregulation when compared with those transfected with control miR. However, the 
expression level of C-PARP was not increased in the miR-93 or miR-106b-transfected 
SaOS-2 cells, although transfection with miR-93 or miR-106b moderately decreased p21 
expression. These results suggest that OBP-702 suppresses p21 expression through 
E1A-dependent upregulation of E2F1-inducible both miR-93 and miR-106b and 
contributes to induction of apoptosis. 
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Increased induction of autophagy by OBP-702 when compared with OBP-301 
Recently, we demonstrated that oncolytic adenovirus OBP-301 mainly induces 
programmed cell death in association with autophagy rather than apoptosis in human 
tumor cells (31). Therefore, we next investigated whether OBP-702 induces more 
profound autophagy than does OBP-301. Western blot analysis revealed that OBP-702 
infection showed increased autophagy, which was confirmed by conversion of LC3-I to 
LC3-II (increased ratio of LC3-II/LC3-I) and p62 downregulation, when compared with 
OBP-301 in MNNG/HOS cells (Fig. 4A). Moreover, the expression level of the 
p53-induced modulator of autophagy, DRAM (32), was decreased after OBP-301 
infection, but its expression was maintained after OBP-702 infection (Fig. 4A). Since 
p53-mediated p21 overexpression is known to inhibit both apoptosis and autophagy (17, 
18), we further evaluated whether miR-mediated p21 suppression is involved in the 
enhancement of p53-mediated autophagy induction. Ad-p53-induced autophagy was 
enhanced by miR-93 and miR-106b -mediated p21 suppression (Fig. 4B). These results 
suggest that OBP-702 induces more profound autophagy than does OBP-301 and that 
this effect occurs via p53-mediated DRAM activation and miR-mediated p21 
suppression. 
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Enhanced antitumor effect of OBP-702 in an orthotopic xenograft tumor model 
Finally, to assess the in vivo antitumor effect of OBP-702, we used an 
orthotopic MNNG/HOS tumor xenograft model. OBP-702, OBP-301, Ad-p53 or PBS 
was intratumorally injected for three cycles every 2 days. OBP-702 administration 
significantly suppressed tumor growth when compared with OBP-301, Ad-p53 or PBS 
in an orthotopic MNNG/HOS tumor model (Fig. 5A and B). 3D-CT examination 
revealed that OBP-702-treated tumors had less bone destruction than did OBP-301- or 
Ad-p53-treated tumors (Fig. 5C). On histopathologic analysis, there were large necrotic 
areas in OBP-702-treated tumors, but not in OBP-301- or Ad-p53-treated tumors (Fig. 
5D). Moreover, the expression of the cell proliferation marker, Ki67, was also decreased, 
especially in OBP-702-treated tumor cells (Supplementary Fig. S6). These results 
suggest that OBP-702 eliminates tumor tissues more efficiently when compared with 
OBP-301 or Ad-p53. 
 
Discussion 
 
We previously reported that telomerase-specific replication-competent 
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oncolytic adenovirus OBP-301 has strong antitumor activity in a variety of human 
epithelial and non-epithelial malignant cells (12, 14, 27). However, some human 
osteosarcoma cells were resistant to the cytopathic activity of OBP-301 (14). In this 
study, we demonstrated that a novel p53-expressing oncolytic adenovirus, OBP-702, 
had increased in vitro and in vivo antitumor effects than did OBP-301 in human 
osteosarcoma cells (Fig. 1 and 5). OBP-702 induced increased apoptosis in association 
with p53 upregulation and p21 downregulation when compared with 
replication-deficient Ad-p53 (Fig. 2 and 3A). E1A-dependent upregulation of miR-93 
and miR-106b was involved in OBP-702-mediated suppression of p21 expression (Fig. 
3). Moreover, p53-mediated DRAM activation with p21 suppression enhanced oncolytic 
adenovirus-mediated autophagy induction (Fig. 4). Recent studies suggest that 
transgene-expressing armed oncolytic adenoviruses are a promising antitumor strategy 
for induction of oncolytic and transgene-induced cell death (33). Although p53 
overexpression has been shown to enhance antitumor activity of oncolytic adenoviruses 
(34), the molecular mechanisms by which p53 mediates enhancement of the antitumor 
effect remain unclear. Recently, we reported that OBP-702 induces profound apoptosis 
through p53-dependent BAX upregulation and E1A-dependent p21 and MDM2 
downregulation in epithelial malignant cells (26). Thus, oncolytic adenovirus-mediated 
Hasei et al., Page 23 
p53 overexpression likely induces dual apoptotic and autophagic cell death pathways 
through p53-dependent BAX/DRAM activation and E1A-dependent p21/MDM2 
suppression with E2F1-inducible miR-93/106b upregulation (Fig. 6). 
OBP-702 efficiently suppressed the cell viability of both OBP-301-sensitive 
and OBP-301-resistant osteosarcoma cells (Fig. 1). We previously reported that 
OBP-301-resistant SaOS-2 cells have no hTERT mRNA expression (Table 1), 
suggesting that SaOS-2 cells maintain telomere length through alternative lengthening 
of telomeres (ALT). As hTERT gene promoter is used for tumor-specific replication of 
OBP-301, ALT-type human osteosarcoma cells like SaOS-2 cells may be resistant to 
OBP-301. However, ALT-type SaOS-2 cells showed similar sensitivity to OBP-702 as 
well as non-ALT-type MNNG/HOS cells (Fig. 1 and Table 1). These results suggest that 
p53 overexpression overcomes resistance to OBP-301 in ALT-type SaOS-2 cells. Since 
the replication rate of OBP-702 was almost similar that of OBP-301 in ALT-type 
SaOS-2 cells (Supplementary Fig. S4), p53-induced cell death pathway would suppress 
the cell viability of ALT-type human osteosarcoma cells. 
OBP-702-mediated p53 overexpression induced two types of programmed cell 
deaths (i.e., apoptosis and autophagy), thereby contributing to the enhancement of the 
antitumor effect of OBP-301 in human osteosarcoma cells (Fig. 2 and 4). Since 
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p53-downstream target p21 functions as a suppressor of apoptosis and autophagy (17, 
18), p21 suppression may be a critical factor to induce dual programmed cell death 
pathways in response p53 overexpression. Suppression of p21 expression by genetic 
deletion or artificial p21-target microRNA has been shown to enhance the 
Ad-p53-induced apoptosis (18, 35). Inactivation of p21 by adenoviral E1A has been 
shown to enhance apoptosis in chemotherapeutic drug-treated human colon cancer cells 
that overexpress p53 (36). Genetic deletion of p21 has been also shown to induce 
autophagy in mouse embryonic fibroblasts treated with C(2)-ceramide or 
gamma-irradiation (17). In contrast, p21 overexpression inhibited the Ad-p53-mediated 
apoptosis induction (18). Thus, E1A-mediated p21 downregulation would enhance 
p53-induced apoptosis and autophagy in OBP-702-infected cells. 
E1A-dependent E2F1 activation and subsequent upregulation of 
E2F1-inducible miRNAs efficiently suppressed p21 expression, leading to the 
enhancement of p53-induced apoptosis and autophagy, in OBP-702-infected 
osteosarcoma cells (Fig. 2, 3 and 4). Recent studies suggest that the cross-talk between 
p53 and E2F1 play a role in the regulation of diverse cell fates (37). For example, 
co-expression of p53 and E2F1 contributes to induction of apoptosis (38, 39). We 
previously demonstrated that E2F1 enhanced Ad-p53-mediated apoptosis through 
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p14ARF-dependent MDM2 downregulation (39) and that OBP-702 infection showed 
E1A-dependent MDM2 downregulation in association with apoptosis (26). Recently, 
E2F1 has been shown to suppress MDM2 expression by suppressing the promoter 
activity (40) or by inducing upregulation of miR-25/32, which targets MDM2 (41). 
Furthermore, E2F1-inducible miR-93/106b enhanced Ad-p53-induced apoptosis and 
autophagy via p21 suppression (Fig. 3D and 4B). Therefore, the cooperation between 
the MDM2-p53-p21 pathway and the E2F1-miRNA pathway may be involved in the 
induction of apoptotic and autophagic cell death in response to OBP-702. 
OBP-702-mediated p53 overexpression enhanced autophagy that was induced 
by oncolytic adenovirus in human osteosarcoma cells. OBP-702 infection induced 
increased expression of DRAM and decreased expression of p62 when compared with 
OBP-301 (Fig. 4), suggesting that OBP-702-mediated p53 overexpression enhances 
autophagy through DRAM activation. We recently reported that OBP-301 induces 
autophagy through E1A-dependent activation of E2F1-miR-7 pathway and subsequent 
suppression of epidermal growth factor receptor (EGFR) (31). Restoration of p53 
expression enhances the sensitivity to EGFR inhibitors in human cancer cells (42). 
Moreover, EGFR downregulation by transfection of specific antisense oligonucleotide 
promotes the differentiation status of human osteosarcoma U2OS cells (43). Thus, 
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OBP-702 may induce differentiation as well as cell death through autophagy activation 
by DRAM upregulation and EGFR downregulation in human osteosarcoma cells. 
The 3D-CT imaging system was a useful method to assess both tumor volume 
and bone destruction status in MNNG/HOS tumors. OBP-702-treated tumors were 
smaller and had less bone destruction when compared with PBS-, Ad-p53- or 
OBP-301-treated tumors (Fig. 5A and 5C). Recent reports have suggested that 
zoledronic acid suppresses tumor growth as well as osteolytic components in human 
osteosarcoma xenograft tumor models (44, 45). These results suggest that combination 
therapy with OBP-702 and zoledronic acid may be more effective and more protective 
against bone destruction in human osteosarcomas. Further study using a 3D-CT imaging 
system may provide important information regarding bone destruction status in 
osteosarcomas treated with OBP-702 and zoledronic acid. 
Adenovirus-mediated p53 gene therapy exerts an antitumor effect in human 
osteosarcoma cells (46). However, the antitumor activity of replication-deficient Ad-p53 
is limited in some human osteosarcoma cells (47). Ad-p53-mediated p53 overexpression 
increases the sensitivity of human osteosarcoma cells to the chemotherapeutic drugs, 
cisplatin and doxorubicin (48). A synergistic antitumor effect between doxorubicin and 
roscovitine was also associated with autophagy induction in human osteosarcoma U2OS 
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cells (49). As OBP-702 induced more profound apoptosis and autophagy than did 
OBP-301 or Ad-p53 (Fig. 2 and 4), combination therapy with OBP-702 and 
chemotherapeutic agents may be more effective than monotherapy with OBP-702. 
Moreover, a recent report has shown that p53-armed replication-competent oncolytic 
adenovirus is a safe antitumor agent in rodents and nonhuman primates (50). However, 
for clinical application of OBP-702, it must be necessary to establish the systemic 
delivery method and confirm the host biological contributions in cancer patients. 
Although there are some unsolved issues, the combination of p53-armed oncolytic 
adenovirus and chemotherapy may provide us a promising antitumor strategy against 
human osteosarcoma cells. 
In conclusion, we clearly demonstrated that the p53-expressing oncolytic 
adenovirus OBP-702 has a much stronger antitumor effect than does OBP-301. 
Oncolytic adenovirus-mediated p53 gene transduction may induce dual apoptotic and 
autophagic cell death pathways through p53-dependent activation of cell death inducers 
and E1A-dependent suppression of cell death inhibitors, resulting in the enhancement of 
antitumor effect. 
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Table 1. Comparison of ID50 values of OBP-301 and OBP-702 in various human osteosarcoma cell lines 
  
 Cell lines 
Sensitivity     
to OBP-301 
Cell 
type* 
Relative hTERT 
mRNA expression  
ID50 value** (MOI) Ratio
†
 
 
 
OBP-301 OBP-702 (OBP-702/OBP-301) 
 
                  
 
SaOS-2 Resistant ALT negative 98.1 5.5 0.06  
 
 
MNNG/HOS Resistant non-ALT 1 97.3 6.7 0.07  
 
 
U2OS Sensitive ALT 0.3 38.2 1.2 0.03  
 
 
HOS Sensitive non-ALT 4.3 43.0  4.5 0.10  
 
                  
         * Alternative lengthening of telomeres (ALT).   
** The ID50 values of OBP-702 and OBP-301 were calculated from the data of XTT assay on day 5 after infection. 
 
†
 The ratio was calculated from the division of the ID50 value of OBP-702 by the ID50 value of OBP-301. 
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Figure legends 
 
Fig. 1. In vitro cytopathic effect of OBP-702 in human osteosarcoma cell lines. A, 
OBP-301-sensitive (HOS and U2OS) and OBP-301-resistant (SaOS-2 and 
MNNG/HOS) human osteosarcoma cells were infected with OBP-702 at the indicated 
multiplicity of infection (MOI), and cell viability was quantified over 5 days using the 
XTT assay. Cell viability was calculated relative to that of the mock-infected group on 
each day, which was set at 1.0. Cell viability data are expressed as mean values ± SD (n 
= 5). B, four human osteosarcoma cells and one normal fibroblast NHLF cells were 
seeded 24 h before viral infection, and were infected with OBP-702 at the indicated 
MOIs, and cell viability was examined on day 5 using the XTT assay. Cell viability was 
calculated relative to that of the mock-infected group, which was set at 1.0. Cell 
viability data are expressed as mean ± SD (n = 5). C, time-lapse images of cytopathic 
effect of OBP-702 in co-culture of green fluorescent protein (GFP)-expressing 
MNNG/HOS cells with human normal fibroblast NHLF cells. MNNG/HOS-GFP cells 
co-incubated with NHLF cells were recorded for 72 h after OBP-702 infection at an 
MOI of 10. Three images on the left are low-magnification, and one image on the right 
is high-magnification of the area outlined by a white square. Left scale bars, 100 μm. 
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Right scale bar, 10 μm. 
 
Fig. 2. OBP-702 induces increased apoptosis when compared with OBP-301 or 
Ad-p53. A, OBP-301-resistant SaOS-2 and MNNG/HOS cells were infected with 
OBP-702 or Ad-p53 at the indicated MOIs for 72 h. Cell lysates were subjected to 
Western blot analysis for the cleaved PARP (C-PARP) and PARP. β-actin was assayed 
as a loading control. B-D, SaOS-2 and MNNG/HOS cells were infected with OBP-702, 
OBP-301 or Ad-p53 at an MOI of 10 for 48 h. Mock-infected cells were used as control. 
Caspase-3 activation was quantified using the flow cytometric analysis. Representative 
flow cytometric data were shown (B). The mean percentage of SaOS-2 cells and 
MNNG/HOS cells that express active caspase-3 was calculated based on 
three-independent experiments (C). The cell cycle state was analyzed by flow cytometry 
in SaOS-2 cells after staining with propidium iodide. Representative cell cycle data 
were shown (D). The percentage of sub-G1 population was expressed in each graph. 
Bars, SD. Statistical significance was determined using Student’s t test. *, P < 0.05. 
 
Fig. 3. OBP-702 induces p53 overexpression with E1A-mediated p21 suppression 
via miR-93 and miR-106b activation. A, expression of the p53 and p21 proteins in 
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SaOS-2 and MNNG/HOS cells infected with OBP-702 or Ad-p53 at the indicated MOIs 
for 72 h was assessed using Western blot analysis. B, expression of the E2F1 and viral 
E1A proteins in SaOS-2 and MNNG/HOS cells infected with OBP-702 at the indicated 
MOIs for 72 h was assessed using Western blot analysis. C, expression of miR-93 and 
miR-106b was assayed using qRT-PCR in SaOS-2 cells infected with OBP-702 at the 
indicated MOIs for 72 h on three-independent experiments. The values of miR-93 and 
miR-106b at 0 MOI were set at 1, and the relative levels of miR-93 and miR-106b at the 
indicated MOIs were plotted as fold induction. Bars, SD. Statistical significance was 
determined by Student’s t test. *, P < 0.05. D, SaOS-2 cells were transfected with 10 
nM miR-93, miR-106 or control miRNA 24 h before Ad-p53 infection at an MOI of 100. 
At 48 h after Ad-p53 infection, the expression levels of p53, p21, PARP and cleaved 
PARP (C-PARP) were examined by Western blot analysis. -actin was assayed as a 
loading control. By using ImageJ software, the expression level of C-PARP protein was 
calculated relative to its expression in the control miR-treated cells, whose expression 
level was designated as 1.0. 
 
Fig. 4. OBP-702 induces increased autophagy when compared with OBP-301. A, 
MNNG/HOS cells were infected with OBP-702 or OBP-301 at the indicated MOIs for 
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72 h. Cell lysates were subjected to Western blot analysis for LC3, p62 and DRAM. B, 
SaOS-2 cells were transfected with 10 nM miR-93, miR-106 or control miRNA 24 h 
before Ad-p53 infection. At 48 h after Ad-p53 infection at an MOI of 100, the 
expression levels of LC3, p62 and DRAM were examined by Western blot analysis. 
β-actin was assayed as a loading control. By using ImageJ software, the ratio of 
LC3-II/LC3-I expressions was calculated relative to its expression in the mock-infected 
cells, whose expression level was designated as 1.0. 
 
Fig. 5. Antitumor effect of OBP-702 in an orthotopic MNNG/HOS osteosarcoma 
xenograft model. A, athymic nude mice were inoculated intratibially with 
MNNG/HOS cells (5 × 10
6
 cells/site). Twenty-one days after inoculation (designated as 
day 0), Ad-p53, OBP-301 or OBP-702 was injected into the tumor with 1 × 10
8
 PFUs on 
days 0, 2 and 4 (black arrows). PBS was used as a control. Three mice were used for 
each group. Each tumor volume was assessed by computed tomography (CT) 
examination. Tumor growth was expressed as mean tumor volume ± SD. Statistical 
significance was determined by Student’s t test. *, P < 0.05. B, macroscopic appearance 
of MNNG/HOS tumors in nude mice on days 0 and 28 after treatment with PBS, 
Ad-p53, OBP-301 or OBP-702. Tumor masses are outlined by a dotted line. C, 
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three-dimensional (3D)-CT images of MNNG/HOS tumors. The tumor volumes were 
calculated by the image viewer (INTAGE Realia) based on 3D-CT images of tumors 
after trimming. The white arrowheads indicate the osteolytic areas within tumor tissues 
treated with PBS, Ad-p53 or OBP-301. Left side images are low-magnification, and 
right side images are high-magnification of the area outlined by a white square. D, 
histological analysis of the MNNG/HOS tumors. Tumor tissues were obtained on day 
28 after first treatment with PBS, Ad-p53, OBP-301 or OBP-702. Paraffin-embedded 
sections of MNNG/HOS tumors were stained with hematoxylin and eosin solutions. 
There were large necrotic areas in MNNG/HOS tumors treated with OBP-702. Left side 
images are low-magnification, and right side images are high-magnification of the area 
outlined by a white square. Left scale bars, 500 μm. Right scale bars, 100 m. 
 
Fig. 6. Outline of OBP-702-mediated induction of dual programmed cell death 
pathways. OBP-702 infection induces apoptosis and autophagy, leading to cell death, 
through p53-dependent BAX/DRAM upregulation and E1A-dependent p21 
downregulation via E2F1-inducible miR-93/106b activation. 
